Canadian energy exploration and development company Standard Lithium Ltd. (TSX.V: SLL) (FRA: S5L) (OTCQX: STLHF) this morning announced its entry into a memorandum of understanding with TETRA Technologies, Inc. (NYSE: TTI) aimed at securing access to additional operating and permitted land consisting of approximately 12,100 acres in Bristol Dry Lake and up to 11,840 acres in the adjacent Cadiz Dry Lake in California’s Mojave Desert. With these additions, Standard Lithium now has access to approximately 48,000 acres of mixed private, patented and placer claim land in the Bristol Dry Lake and Cadiz Dry Lake basins, allowing it exclusive lithium brine exploration and processing rights. “Since day one we have recognized the bigger opportunity with respect to expanding the resource base and strengthening project economics at Bristol Dry Lake by securing the rights for lithium development over the entire basin,” Robert Mintak, CEO of Standard Lithium, stated in the news release. “By inking an agreement with TETRA, the only other permitted operator in the area, we have now effectively achieved that. This is a significant and strategic move for Standard, but has only been made possible by the excellent relationships we have developed with the permitted brine operators in the region.”
To view the full press release, visit http://dtn.fm/1vHal
About Standard Lithium
Standard’s value creation strategy encompasses acquiring a diverse and highly prospective portfolio of large-scale domestic brine resources, led by an innovative and results-oriented management team with a strong focus on technical skills. The Company is currently focused on the immediate exploration and development of the Bristol Dry Lake Lithium Project located in the Mojave region of San Bernardino County, California; the location has significant infrastructure in-place, with easy road and rail access, abundant electricity and water sources, and is already permitted for extensive brine extraction and processing activities. The Company is also commencing due diligence and resource evaluation on 33,000 acres of lithium brine leases located in the Smackover Formation. For more information, visit the company’s website at www.standardlithium.com
About MissionIRNewsBreaks
MissionIRNewsBreaks provide a rapid summary of corporate news that catch the attention of MissionIR. MissionIRNewsBreaks are created by our Team of professional journalists that keep a constant eye on the markets, these posts are designed to inform you on the latest happenings of our clients and other publicly traded companies on our radar. From earnings, acquisitions and agreements to conference attendance and clinical study results, our news breaks keep you up-to-date with the day’s top movers. MissionIR is primarily focused on strategic communications. We have executed countless communications programs to address the needs of companies ranging from start-ups to established industry leaders, gaining valuable experience and the expertise necessary to determine the most effective strategy for any given situation.
MissionIR (MIR)
Atlanta, Georgia
www.MissionIR.com
404.941.8975 Office
Editor@MissionIR.com
Please see full terms of use and disclaimers on the Mission Investor Relations website applicable to all content provided by MIR, wherever published or re-published: http://www.missionir.com/disclaimer.html
Monday, October 30, 2017
Friday, October 27, 2017
MissionIRNewsBreaks – Moxian, Inc. (NASDAQ: MOXC) Concentrates On Larger Volume Networks in China
Moxian, Inc. (NASDAQ: MOXC) has recently shifted its focus in China in an effort to increase its share of the online-to-offline (O2O) market, grow processing fees, and enhance commission revenues on sales processed by its UnionPay mobile module. An article discussing this reads: “The new strategy is part of MOXC’s shift toward gaining more market share in China with its paid platforms, Moxian+ Merchant App and Moxian+ User App, for consumers. Smaller retailers are attracted to larger volume networks, such as Alibaba’s Taobao platform. Instead, MOXC sees the benefit of faster growth by targeting larger retailers in China.”
To view the full article, visit http://dtn.fm/v7zEl
About Moxian, Inc.
Founded in 2013 in Shenzhen, China with branch offices in Beijing, Malaysia, and Hong Kong, Moxian, Inc. is an offline-to-online (O2O) integrated platform operator. The Company’s “Moxian+” mobile App platform connects Users to Merchant Clients through games, rewards and social events that they enjoy and in return, Users provide valuable information that Merchant Clients can use to effectively promote products and services offered at their brick and mortar stores. More information about the company can be found at www.moxian.com
About MissionIRNewsBreaks
MissionIRNewsBreaks provide a rapid summary of corporate news that catch the attention of MissionIR. MissionIRNewsBreaks are created by our Team of professional journalists that keep a constant eye on the markets, these posts are designed to inform you on the latest happenings of our clients and other publicly traded companies on our radar. From earnings, acquisitions and agreements to conference attendance and clinical study results, our news breaks keep you up-to-date with the day’s top movers. MissionIR is primarily focused on strategic communications. We have executed countless communications programs to address the needs of companies ranging from start-ups to established industry leaders, gaining valuable experience and the expertise necessary to determine the most effective strategy for any given situation.
MissionIR (MIR)
Atlanta, Georgia
www.MissionIR.com
404.941.8975 Office
Editor@MissionIR.com
Please see full terms of use and disclaimers on the Mission Investor Relations website applicable to all content provided by MIR, wherever published or re-published: http://www.missionir.com/disclaimer.html
To view the full article, visit http://dtn.fm/v7zEl
About Moxian, Inc.
Founded in 2013 in Shenzhen, China with branch offices in Beijing, Malaysia, and Hong Kong, Moxian, Inc. is an offline-to-online (O2O) integrated platform operator. The Company’s “Moxian+” mobile App platform connects Users to Merchant Clients through games, rewards and social events that they enjoy and in return, Users provide valuable information that Merchant Clients can use to effectively promote products and services offered at their brick and mortar stores. More information about the company can be found at www.moxian.com
About MissionIRNewsBreaks
MissionIRNewsBreaks provide a rapid summary of corporate news that catch the attention of MissionIR. MissionIRNewsBreaks are created by our Team of professional journalists that keep a constant eye on the markets, these posts are designed to inform you on the latest happenings of our clients and other publicly traded companies on our radar. From earnings, acquisitions and agreements to conference attendance and clinical study results, our news breaks keep you up-to-date with the day’s top movers. MissionIR is primarily focused on strategic communications. We have executed countless communications programs to address the needs of companies ranging from start-ups to established industry leaders, gaining valuable experience and the expertise necessary to determine the most effective strategy for any given situation.
MissionIR (MIR)
Atlanta, Georgia
www.MissionIR.com
404.941.8975 Office
Editor@MissionIR.com
Please see full terms of use and disclaimers on the Mission Investor Relations website applicable to all content provided by MIR, wherever published or re-published: http://www.missionir.com/disclaimer.html
Thursday, October 26, 2017
Moxian, Inc. (NASDAQ: MOXC) Blazes New Direction with Change in Leadership
- Redefining profitability in large retailer market
- Hao Qing Hu named chief executive officer in September
- Mobile apps aim to turn consumers into companies’ fans
The new executive leadership of a growing O2O app maker that helps retailers network with their customers is forging ahead with efforts to redefine its own business model and increase its profitability.
Less than a month after announcing (http://dtn.fm/i2bEE) that Hao Qing Hu would take over the reins as chief executive officer of Moxian, Inc. (NASDAQ: MOXC), the company’s data-driven Social Customer Relationship Management system has begun shifting its focus toward helping large retailers build reward incentives to draw customers into their stores (http://dtn.fm/yd4mB).
Moxian’s online-to-offline (O2O) mobile apps for consumers and businesses are designed to help companies turn their customers into fans who will return again and again through the use of game-driven loyalty points and the nimble responsiveness of instant message replies to questions. The apps also provide businesses with analytical insights on customer trends with tools they can use to boost their revenues. Together, the apps offer a one-stop shop at both ends of the retail pipeline to help customers find the products they enjoy and businesses find the revenues they need.
The company’s shift away from working with smaller mom-and-pop businesses reflects an effort to identify the greatest likelihood for revenue growth amid a competitive marketplace, primarily in China, where Moxian is based and about a fifth of the world’s population is located.
Moxian is converting its Moxian+ User and Merchant app platforms to a paid-for product that enables revenue-generating subscriptions and marketing.
In 2016, Moxian was presented with an award for Best Solution Award of Social Media Marketing by the Big Data Industry Alliance of China and the China Center for Information Industry Development (http://dtn.fm/IAzK5).
Crystal Equity Research projects the company’s sales will reach $2.3 million during the coming fiscal year with profits of $1.7 million (http://dtn.fm/9yDsp).
For more information, visit the company’s website at www.Moxian.com
About MissionIR
MissionIR is primarily focused on strategic communications. We have executed countless communications programs to address the needs of companies ranging from start-ups to established industry leaders, gaining valuable experience and the expertise necessary to determine the most effective strategy for any given situation.
For more information, visit www.MissionIR.com
MissionIR (MIR)
Atlanta, Georgia
www.MissionIR.com
404.941.8975 Office
Editor@MissionIR.com
Please see full terms of use and disclaimers on the Mission Investor Relations website applicable to all content provided by MIR, wherever published or re-published: http://www.missionir.com/disclaimer.html
Wednesday, October 25, 2017
Pressure BioSciences, Inc. (PBIO) Game-Changing Pressure Cycling Technology Is Revolutionizing Scientific Research at the Most Fundamental Level
- Company is positioned to disrupt the $6 billion global life sciences sample preparation market
- Pressure Cycling Technology (PCT) is a game-changer in bolstering the quality and efficacy of scientific research
- Next generation Barocycler 2320EXTREME instrument is becoming a crucial research tool in “Cancer Moonshot” laboratories and has been named a finalist in the prestigious 2017 R&D 100 Awards (the “Oscars of Innovation”)
The first steps in any process are some of the most crucial, as the earliest steps along a path often direct the entire course of a journey. Similarly, the beginnings of any scientific endeavor influence all other aspects going forward. Understanding this fundamental truth, Pressure BioSciences, Inc. (OTCQB: PBIO) is revolutionizing scientific research from the very earliest steps (i.e., sample preparation).
Serving the $6 billion life sciences sample preparation market, PBIO offers a game-changing product line that can control the critical sample preparation process in an unprecedented way, enabling researchers to start their experimentation with samples of unmatched quality. In any type of scientific research, the quality of the sample one begins with hugely affects the efficacy, outcome and importance of the research. The ability to reproducibly create high quality samples for testing and research is unquestionably impactful and has applications in a wide variety of scientific research and discovery areas.
PBIO’s product line is based on a patented, enabling technology platform called pressure cycling technology (PCT), which employs alternating cycles of hydrostatic pressure—ranging between ambient (14.5 psi) and ultra-high levels (up to 100,000 psi)—to safely and reproducibly control critical biological processes. For example, one of these processes is lysis, or the breakage of cells.
Traditionally, when cells are ruptured for study, they must be broken open using chemicals, blades, metal beads, sound waves or other inadequate methods that can damage and alter the invaluable biomolecules inside the cells they are breaking (e.g., DNA, proteins and lipids), thereby negatively impacting the efficacy of the research performed using the biomolecules. With PBIO’s pioneering PCT technology, however, the lysis process is controlled like never before. Customized, controlled cycles of hydrostatic (water) pressure are used to rupture the cells in a controlled manner, inside a very safe pressure chamber. The pressure is exquisitely controlled and customized to an exact level of PSI, according to the type of cells being broken, enabling the optimum amount of pressure to be delivered to rupture the cell in an ideal and reproducible way (e.g., not too much pressure and not too little) —something that has never before been accomplished in a commercial setting.
The potential impact of this innovative method is astronomical, enabling the creation of truer, more legitimate samples for analysis, which allows research scientists to commence their studies with biological samples of unmatched integrity. The resulting impact on the efficacy and outcomes of scientific research is potentially enormous.
Through PCT, pathogens like viruses and bacteria can further be inactivated through the use of hydrostatic pressure, which makes such samples far safer to study. This is yet another PBIO innovation with astounding potential applications in a wide variety of markets.
The lead product in the PBIO line is the newly released, next-generation Barocycler 2320EXTREME instrument, which has been named a finalist in the prestigious 2017 R&D 100 Awards (also known as the “Oscars of Innovation”). This exciting instrument is being hailed as an essential component of the United States’ $1.8 billion “Cancer Moonshot” program by a number of Moonshot researchers. Professor Phil Robinson, co-head of the Children’s Medical Research Institute cancer research center (Sydney, Australia) and the first international Cancer Moonshot collaborator, recently stated, “Due to its unique capabilities, the Barocycler 2320EXT has become a critical part of our program. It is the primary enabler of the high-throughput component of the project. Without this step, our project simply could not be done. In fact, the Barocycler 2320EXT works so well we have just purchased two more.”
PBIO markets its pioneering PCT-based instruments throughout the U.S., Canada, Europe, Australia, Japan and China. The chief applications of PCT technology are in biomarker discovery, forensics, agriculture and pathology (preparation of tissue biopsy samples for analysis). This wave-making technology is also being applied in the specialized fields of drug discovery and design, biotherapeutics characterization, soil and plant biology, vaccine development and histology.
For further information about Pressure BioSciences, the company’s PCT technology and various other innovative offerings, visit the company’s website at www.PressureBioSciences.com
About MissionIR
MissionIR is primarily focused on strategic communications. We have executed countless communications programs to address the needs of companies ranging from start-ups to established industry leaders, gaining valuable experience and the expertise necessary to determine the most effective strategy for any given situation.
For more information, visit www.MissionIR.com
MissionIR (MIR)
Atlanta, Georgia
www.MissionIR.com
404.941.8975 Office
Editor@MissionIR.com
Please see full terms of use and disclaimers on the Mission Investor Relations website applicable to all content provided by MIR, wherever published or re-published: http://www.missionir.com/disclaimer.html
India Globalization Capital, Inc. (NYSE: IGC) Could Release Potential Blockbuster Alzheimer’s Treatment in Early 2018
- On the verge of releasing potential Cannabis-based blockbuster Alzheimer’s treatment
- Company is able to hugely accelerate release of this treatment in recreational cannabis states
- Market potential for drugs to treat and prevent Alzheimer’s is in the billions of dollars
According to information from the Alzheimer’s Association, approximately 47 million people are living with dementia throughout the world—a figure that has been projected to rise to 76 million by 2030. There is still no cure for this devastating disease. However, India Globalization Capital, Inc. (NYSE MKT: IGC) is on the precipice of bringing a potential blockbuster treatment for Alzheimer’s to the market—an event that could happen by early 2018.
Recently, IGC announced it is readying a line of cannabis-based products targeting Alzheimer’s disease based on novel data (http://dtn.fm/h35qX). The company has been engineering genetic cell lines that show the protein Aβ decreases by as much as 40 percent at various concentrations of tetrahydrocannabinol (THC) without neuron damage. (Amyloid beta peptides, or Aβ plaque, buildup in the brain is believed to be the chief cause of Alzheimer’s). This compelling in vitro data shows tremendous promise for treating and even preventing Alzheimer’s.
“As Alzheimer’s progresses, synaptic dysfunction and the death of neurons lead to memory loss. These study results, when combined with the earlier reported data that shows IGC-AD1 reduces Aβ40 and Aβ42 production by as much as 50%, and 40%, without any toxicity, represent a highly significant novel breakthrough that could potentially bring much needed relief from this devastating disease,” IGC CEO Ram Mukunda said, as quoted in the press release.
IGC currently has four products in its pipeline: Hyalolex, which is the company’s breakthrough treatment aimed at reducing beta-amyloid building up in Alzheimer’s patients; Natrinol, or synthetic THC, which has application for relieving nausea, vomiting and loss of appetite in patients with AIDS and cancer; Caesafin, which uses combination therapy to assuage seizures in dogs and cats; and Serosapse, which addresses various endpoints in Parkinson’s disease.
Typically, pharmaceutical companies are only able to market a product once it has received FDA approval, which involves a very lengthy and expensive process. Because IGC is using a combination therapy, the company is able to bring products to market significantly faster and at a substantially lower cost. IGC is actually able to bring some of its products to market in a matter of months rather than years by bringing them to cannabis medical dispensaries. The company’s breakthrough Alzheimer’s treatment is one such product.
This hugely accelerated introduction of Hyalolex can only be accomplished in states where medical cannabis is legal and where the ailment (in this case Alzheimer’s) is an approved medical condition. In states where recreational cannabis has been approved, IGC doesn’t have to contend with whether or not Alzheimer’s is an approved medical condition in order to bring its treatment to market. Therefore, these states (recreational marijuana states like California, Colorado, Oregon, etc.) will be targeted first with IGC’s cannabis-based Alzheimer’s treatment.
In view of IGC’s pipeline, consisting of Hyalolex for the treatment of Alzheimer’s and other phytocannabinoid-based therapies, the company’s market valuation is poised to explode. Investors have made Alzheimer’s treatment drugs a high priority in the biotechnology field, and the market potential for a preventative Alzheimer’s treatment is in the billions of dollars. Some of IGC’s Alzheimer’s-focused competitors already have market valuations in the hundreds of millions or billions of dollars—making the sky the limit for IGC’s future growth.
For more information, visit the company’s website at www.IGCInc.us
About MissionIR
MissionIR is primarily focused on strategic communications. We have executed countless communications programs to address the needs of companies ranging from start-ups to established industry leaders, gaining valuable experience and the expertise necessary to determine the most effective strategy for any given situation.
For more information, visit www.MissionIR.com
MissionIR (MIR)
Atlanta, Georgia
www.MissionIR.com
404.941.8975 Office
Editor@MissionIR.com
Please see full terms of use and disclaimers on the Mission Investor Relations website applicable to all content provided by MIR, wherever published or re-published: http://www.missionir.com/disclaimer.html
Arcimoto (NASDAQ: FUV) Prepares to Roll Out ‘Fun’ Eco-Friendly Platform
- Three-wheeled FUV can reach 85 mph, accelerating from 0 to 60 in 7.5 seconds
- New Eugene, Oregon, manufacturing plant will celebrate grand opening on November 11
- Debuted on Nasdaq exchange in September with 1,821 customer pre-orders already in place as of first investor call
Arcimoto Inc. (NASDAQ: FUV) has spent a decade developing the FUV as an affordable means of transportation that can operate at normal road speeds and help to cut through city traffic, all in a vehicle that’s designed to preserve the riders’ safety while delivering a light impact on the environment.
“I thought if we could build something that was much closer to the motorcycle in terms of efficiency and fun factor and footprint on the road, but was close to the car in terms of capabilities and encloseable and carries groceries and stable, that we’d have a real product opportunity that the world has been missing for a long time,” Arcimoto founder and CEO Mark Frohnmayer told Reuters.
The FUV SRK model can reach 85 mph and accelerate from 0 to 60 in 7.5 seconds. It has a range of 70 miles before recharging, and its fuel consumption is comparable to 230 miles per gallon, according to Frohnmayer.
The frame offers open-air visibility but has an attachable-detachable shell to enclose riders during inclement weather.
Arcimoto took possession of its 30,000-square-foot Eugene, Oregon, manufacturing plant on October 1 and plans a grand opening on Saturday, November 11, to celebrate the culmination of a decade of prototype development on the road to large-scale production.
The company debuted on the Nasdaq exchange in September as a Regulation A+ IPO built on a highly successful crowdfunding campaign, and it expects that, by the end of 2018 or early 2019, it will launch its pilot fleet vehicles while beginning retail manufacturing at the Phase 1 production facility.
At Arcimoto’s first public investor call on September 28, Frohnmayer said the company already had 1,821 customer pre-orders. Customers exist in every state, but are clustered in states such as Oregon, California, Florida, New York, Texas, New Jersey and Washington, he said.
“We are on the cusp of full production, are building arguably the most efficient everyday electric vehicle company in human history and will begin delivering Fun Utility Vehicles to paying customers, some who’ve waited for many years, next quarter,” Frohnmayer said during the investor call.
For more information, visit the company’s website at www.Arcimoto.com
About MissionIR
MissionIR is primarily focused on strategic communications. We have executed countless communications programs to address the needs of companies ranging from start-ups to established industry leaders, gaining valuable experience and the expertise necessary to determine the most effective strategy for any given situation.
For more information, visit www.MissionIR.com
MissionIR (MIR)
Atlanta, Georgia
www.MissionIR.com
404.941.8975 Office
Editor@MissionIR.com
Please see full terms of use and disclaimers on the Mission Investor Relations website applicable to all content provided by MIR, wherever published or re-published: http://www.missionir.com/disclaimer.html
MissionIRNewsBreaks – India Globalization Capital, Inc. (NYSE: IGC) Enters MOU Related to Import and Distribution of Cannabinoid-Based Therapies in Germany
India Globalization Capital, Inc. (NYSE American: IGC), a developer of cannabis-based therapies to treat a variety of life-altering conditions, this morning announced that it has entered into a memorandum of understanding with MediCann Handels GmbH for the import and distribution of IGC’s cannabinoid-based therapies to pharmacies in Germany. Under the terms of the MOU, MediCann will provide the capital required for the transportation, import, storage, sales and marketing of products intended for the German market. “There are many benefits to developing a strong presence in the German pharmacy market including, a favorable regulatory environment and reimbursement from health insurance providers,” Ram Mukunda, CEO of IGC, stated in the news release. “The agreement with MediCann is the first step in the commercialization process of our therapies, as we work out the logistics of how to efficiently deliver our products to Germany.”
To view the full press release, visit http://dtn.fm/K3Pwf
About IGC
IGC is engaged in the development of cannabis based combination therapies to treat Alzheimer’s, pain, nausea, eating disorders, several end points of Parkinson’s, and epilepsy in dogs and cats. IGC has assembled a portfolio of patent filings and four lead product candidates addressing these conditions. The company is based in Maryland, USA. For more information visit www.igcinc.us
About MissionIRNewsBreaks
MissionIRNewsBreaks provide a rapid summary of corporate news that catch the attention of MissionIR. MissionIRNewsBreaks are created by our Team of professional journalists that keep a constant eye on the markets, these posts are designed to inform you on the latest happenings of our clients and other publicly traded companies on our radar. From earnings, acquisitions and agreements to conference attendance and clinical study results, our news breaks keep you up-to-date with the day’s top movers. MissionIR is primarily focused on strategic communications. We have executed countless communications programs to address the needs of companies ranging from start-ups to established industry leaders, gaining valuable experience and the expertise necessary to determine the most effective strategy for any given situation.
MissionIR (MIR)
Atlanta, Georgia
www.MissionIR.com
404.941.8975 Office
Editor@MissionIR.com
Please see full terms of use and disclaimers on the Mission Investor Relations website applicable to all content provided by MIR, wherever published or re-published: http://www.missionir.com/disclaimer.html
To view the full press release, visit http://dtn.fm/K3Pwf
About IGC
IGC is engaged in the development of cannabis based combination therapies to treat Alzheimer’s, pain, nausea, eating disorders, several end points of Parkinson’s, and epilepsy in dogs and cats. IGC has assembled a portfolio of patent filings and four lead product candidates addressing these conditions. The company is based in Maryland, USA. For more information visit www.igcinc.us
About MissionIRNewsBreaks
MissionIRNewsBreaks provide a rapid summary of corporate news that catch the attention of MissionIR. MissionIRNewsBreaks are created by our Team of professional journalists that keep a constant eye on the markets, these posts are designed to inform you on the latest happenings of our clients and other publicly traded companies on our radar. From earnings, acquisitions and agreements to conference attendance and clinical study results, our news breaks keep you up-to-date with the day’s top movers. MissionIR is primarily focused on strategic communications. We have executed countless communications programs to address the needs of companies ranging from start-ups to established industry leaders, gaining valuable experience and the expertise necessary to determine the most effective strategy for any given situation.
MissionIR (MIR)
Atlanta, Georgia
www.MissionIR.com
404.941.8975 Office
Editor@MissionIR.com
Please see full terms of use and disclaimers on the Mission Investor Relations website applicable to all content provided by MIR, wherever published or re-published: http://www.missionir.com/disclaimer.html
Monday, October 23, 2017
Moxian, Inc. (NASDAQ: MOXC) Shifts Focus to Larger China Retailers to Gain Market Share
- New strategy in China is targeted to gain share in online-to-offline (O2O) market, grow processing fees, and boost revenues from converting its platforms to paid
- Crystal Equity Research has set a $5.25 price on MOXC stock and projects sales of $2.3 million by FY2018 with gross profit of $1.7 million
- China Daily reports retail sales in China grew 10.4% YOY to $2.55 trillion in 1H2017
Moxian, Inc. (NASDAQ: MOXC) is now focusing on larger retailers ($2-$4 million in annual sales) to grow its Moxian+ Merchant App in the Online-To-Offline (O2O) market, setting its sights on more business subscribers, increased commission revenues on sales processed by its UnionPay mobile module, and selling subscriber merchants sophisticated data on consumers.
The new strategy is part of MOXC’s shift towards gaining more market share in China with its paid platforms Moxian+ Merchant App and Moxian+ User App, for consumers. Smaller retailers are attracted to larger volume networks, such as Alibaba’s Taobao platform. Instead, MOXC sees the benefit of faster growth by targeting larger retailers in China.
MOXC is a Shenzhen, China-based development-stage company working to convert its formerly-free platforms into paid apps that generate revenues from subscriptions, advertising, marketing, and fees earned from payments processed by its UnionPay module.
Crystal Equity Research has set a $5.25 price on MOXC stock and projects its sales will reach $2.3 million by FY2018 with a gross profit of $1.7 million (http://dtn.fm/tR8Vq). China Daily reports that first half 2017 retail sales grew 10.4% YOY to $2.55 trillion in 1H2017 (http://dtn.fm/e5gIL).
MOXC’s strategy shift is also repositioning its sales managers to work with independent agents by market. Within four years, the company anticipates building networks with 500-1,000 agents in each market. The goal is lower SG&A expenses and better align expenses to revenue streams from new customers, the report said.
Previously, MOXC’s strategy was to pursue smaller retailers. But a lot of O2O competition for that business is a factor — making it inefficient and costly for MOXC to grow market share. By targeting larger retailers, MOXC now sees opportunity to process more sales and earn more revenue as a percentage of those sales. The company can also charge larger retailers fees by offering additional data that targets the Chinese digital consumer market.
For more information, visit the company’s website at www.Moxian.com
About MissionIR
MissionIR is primarily focused on strategic communications. We have executed countless communications programs to address the needs of companies ranging from start-ups to established industry leaders, gaining valuable experience and the expertise necessary to determine the most effective strategy for any given situation.
For more information, visit www.MissionIR.com
MissionIR (MIR)
Atlanta, Georgia
www.MissionIR.com
404.941.8975 Office
Editor@MissionIR.com
Please see full terms of use and disclaimers on the Mission Investor Relations website applicable to all content provided by MIR, wherever published or re-published: http://www.missionir.com/disclaimer.html
Wednesday, October 18, 2017
MissionIRNewsBreaks – Moxian, Inc. (NASDAQ: MOXC) Poised to Capitalize on China’s Consumer-Driven Growth
It is estimated that China will experience almost $2 trillion in new consumer-driven consumption by 2021, and Chinese consumers are about twice as likely to use a mobile device to make retail purchases as consumers in Europe and the United States. Right in line to capitalize on this, Moxian, Inc. (NASDAQ: MOXC) has recently upgraded its mobile payments capability as it continues bridging the gap between e-commerce and brick-and-mortar retail, helping move Chinese consumers from online views to in-store purchases at the physical locations of Moxian’s clients. An article discussing this reads: “The company’s seductive social network integrates social media and business into a single platform that offers products, features and services that appeal to consumers, keeping them engaged and referring new customers. The company’s ingenious and captivating online platforms and mobile applications, the Moxian+ User app and the Moxian+ Business app, allow businesses to interface with both new and existing customers. These online interactions provide each business with the data to analyze consumer likes, dislikes and trends. Moxian’s platforms provide businesses with the ability to create, manage and promote individualized customer loyalty programs, targeted advertising campaigns and special promotions. These interactions between users and Moxian’s merchant clients drive retail traffic into the brick and mortar locations and give merchant clients the ability to study consumer behavior and custom-tailor offerings to consumers.”
To view the full article, visit http://dtn.fm/f1lhG
About Moxian, Inc.
Founded in 2013 in Shenzhen, China with branch offices in Beijing, Malaysia, and Hong Kong, Moxian, Inc. is an offline-to-online (O2O) integrated platform operator. The Company’s “Moxian+” mobile App platform connects Users to Merchant Clients through games, rewards and social events that they enjoy and in return, Users provide valuable information that Merchant Clients can use to effectively promote products and services offered at their brick and mortar stores. More information about the Company can be found at www.moxian.com.
About MissionIRNewsBreaks
MissionIRNewsBreaks provide a rapid summary of corporate news that catch the attention of MissionIR. MissionIRNewsBreaks are created by our Team of professional journalists that keep a constant eye on the markets, these posts are designed to inform you on the latest happenings of our clients and other publicly traded companies on our radar. From earnings, acquisitions and agreements to conference attendance and clinical study results, our news breaks keep you up-to-date with the day’s top movers. MissionIR is primarily focused on strategic communications. We have executed countless communications programs to address the needs of companies ranging from start-ups to established industry leaders, gaining valuable experience and the expertise necessary to determine the most effective strategy for any given situation.
MissionIR (MIR)
Atlanta, Georgia
www.MissionIR.com
404.941.8975 Office
Editor@MissionIR.com
Please see full terms of use and disclaimers on the Mission Investor Relations website applicable to all content provided by MIR, wherever published or re-published: http://www.missionir.com/disclaimer.html
To view the full article, visit http://dtn.fm/f1lhG
About Moxian, Inc.
Founded in 2013 in Shenzhen, China with branch offices in Beijing, Malaysia, and Hong Kong, Moxian, Inc. is an offline-to-online (O2O) integrated platform operator. The Company’s “Moxian+” mobile App platform connects Users to Merchant Clients through games, rewards and social events that they enjoy and in return, Users provide valuable information that Merchant Clients can use to effectively promote products and services offered at their brick and mortar stores. More information about the Company can be found at www.moxian.com.
About MissionIRNewsBreaks
MissionIRNewsBreaks provide a rapid summary of corporate news that catch the attention of MissionIR. MissionIRNewsBreaks are created by our Team of professional journalists that keep a constant eye on the markets, these posts are designed to inform you on the latest happenings of our clients and other publicly traded companies on our radar. From earnings, acquisitions and agreements to conference attendance and clinical study results, our news breaks keep you up-to-date with the day’s top movers. MissionIR is primarily focused on strategic communications. We have executed countless communications programs to address the needs of companies ranging from start-ups to established industry leaders, gaining valuable experience and the expertise necessary to determine the most effective strategy for any given situation.
MissionIR (MIR)
Atlanta, Georgia
www.MissionIR.com
404.941.8975 Office
Editor@MissionIR.com
Please see full terms of use and disclaimers on the Mission Investor Relations website applicable to all content provided by MIR, wherever published or re-published: http://www.missionir.com/disclaimer.html
MissionIRNewsBreaks – Pressure BioSciences, Inc. (PBIO) Enters Collaboration Agreement with Phasex Corporation
Pressure BioSciences, Inc. (“PBI”) (OTCQB: PBIO), a leader in the development and sale of innovative solutions for the worldwide life sciences industry, this morning announced a collaboration with Phasex Corporation, one of the world’s most experienced supercritical fluid (“SCF”)-based toll processors. The goal of the collaboration is to combine PBI’s recently patented Ultra Shear Technology with Phasex’s SCF-based processing methods to enable the development of stable, water-soluble nanoemulsions of nutraceuticals, including CBD-enriched plant oil. “Rapidly expanding markets for non-psychoactive extracts of cannabis plant material, for instance, is an example of a potentially high demand application for our combined, synergistic technologies,” Richard T. Schumacher, president and CEO of PBI, stated in the news release. “Oral bioavailability of CBD in aqueous emulsions has been previously demonstrated in several studies. Combining the capabilities and experience of PBI and Phasex could effectuate commercial scale production of such formulations with long shelf stability, which in turn could potentially result in a highly profitable service model for the PBI and Phasex collaboration.”
To view the full press release, visit http://dtn.fm/7IiPk
About Pressure BioSciences, Inc.
Pressure BioSciences, Inc. (“PBI”) (OTCQB: PBIO) develops, markets, and sells proprietary laboratory instrumentation and associated consumables to the estimated $6 billion life sciences sample preparation market. Our products are based on the unique properties of both constant (i.e., static) and alternating (i.e., pressure cycling technology, or “PCT”) hydrostatic pressure. PCT is a patented enabling technology platform that uses alternating cycles of hydrostatic pressure between ambient and ultra-high levels to safely and reproducibly control bio-molecular interactions. Our primary focus is in the development of PCT-based products for biomarker and target discovery, drug development and design, bio-therapeutics characterization, soil & plant biology, forensics, and counter-bioterror applications. Major new focal market opportunities are emerging in the use of our patented, scalable, high-efficiency Ultra Shear Technology (“UST”) to create stable nanoemulsions of otherwise immiscible fluids (such as oils and water), and to prepare higher quality, homogenized, extended shelf-life or room temperature stable, low-acid liquid foods that cannot be effectively prepared using existing technologies.
About MissionIRNewsBreaks
MissionIRNewsBreaks provide a rapid summary of corporate news that catch the attention of MissionIR. MissionIRNewsBreaks are created by our Team of professional journalists that keep a constant eye on the markets, these posts are designed to inform you on the latest happenings of our clients and other publicly traded companies on our radar. From earnings, acquisitions and agreements to conference attendance and clinical study results, our news breaks keep you up-to-date with the day’s top movers. MissionIR is primarily focused on strategic communications. We have executed countless communications programs to address the needs of companies ranging from start-ups to established industry leaders, gaining valuable experience and the expertise necessary to determine the most effective strategy for any given situation.
MissionIR (MIR)
Atlanta, Georgia
www.MissionIR.com
404.941.8975 Office
Editor@MissionIR.com
Please see full terms of use and disclaimers on the Mission Investor Relations website applicable to all content provided by MIR, wherever published or re-published: http://www.missionir.com/disclaimer.html
To view the full press release, visit http://dtn.fm/7IiPk
About Pressure BioSciences, Inc.
Pressure BioSciences, Inc. (“PBI”) (OTCQB: PBIO) develops, markets, and sells proprietary laboratory instrumentation and associated consumables to the estimated $6 billion life sciences sample preparation market. Our products are based on the unique properties of both constant (i.e., static) and alternating (i.e., pressure cycling technology, or “PCT”) hydrostatic pressure. PCT is a patented enabling technology platform that uses alternating cycles of hydrostatic pressure between ambient and ultra-high levels to safely and reproducibly control bio-molecular interactions. Our primary focus is in the development of PCT-based products for biomarker and target discovery, drug development and design, bio-therapeutics characterization, soil & plant biology, forensics, and counter-bioterror applications. Major new focal market opportunities are emerging in the use of our patented, scalable, high-efficiency Ultra Shear Technology (“UST”) to create stable nanoemulsions of otherwise immiscible fluids (such as oils and water), and to prepare higher quality, homogenized, extended shelf-life or room temperature stable, low-acid liquid foods that cannot be effectively prepared using existing technologies.
About MissionIRNewsBreaks
MissionIRNewsBreaks provide a rapid summary of corporate news that catch the attention of MissionIR. MissionIRNewsBreaks are created by our Team of professional journalists that keep a constant eye on the markets, these posts are designed to inform you on the latest happenings of our clients and other publicly traded companies on our radar. From earnings, acquisitions and agreements to conference attendance and clinical study results, our news breaks keep you up-to-date with the day’s top movers. MissionIR is primarily focused on strategic communications. We have executed countless communications programs to address the needs of companies ranging from start-ups to established industry leaders, gaining valuable experience and the expertise necessary to determine the most effective strategy for any given situation.
MissionIR (MIR)
Atlanta, Georgia
www.MissionIR.com
404.941.8975 Office
Editor@MissionIR.com
Please see full terms of use and disclaimers on the Mission Investor Relations website applicable to all content provided by MIR, wherever published or re-published: http://www.missionir.com/disclaimer.html
MissionIRNewsBreaks – India Globalization Capital, Inc. (NYSE: IGC) Approaching Commercialization of IGC-AD1 in Early 2018
India Globalization Capital, Inc. (NYSE American: IGC), a developer of cannabis-based therapies to treat a variety of life-altering conditions, this morning provided compelling in vitro data compiled from genetically engineered cell lines within an Alzheimer’s disease model showing that, at varying concentrations of IGC-AD1, the expression of GSK3β is reduced by as much as 62 percent. “Based on this and other previously announced compelling data, we are readying IGC-AD1, brand name Hyalolex, in a liquid formulation for commercialization in early 2018,” Ram Mukunda, CEO of IGC, stated in the news release. “We have identified Germany, Canada and certain licensed medical cannabis states in the U.S. for commercialization… Our initial research indicates that there are about 7.8 million patients with AD in these combined markets.” The newly-announced results, when combined with earlier reported data showing that IGC-AD1 reduces Aβ production and inhibits Aβ aggregation without any neuronal toxicity, represent a novel breakthrough toward the treatment of Alzheimer’s, which is known as America’s most expensive disease with an estimated annual cost to the U.S. economy of $236 billion.
To view the full press release, visit http://dtn.fm/vc40E
About IGC
IGC is engaged in the development of cannabis based combination therapies to treat Alzheimer’s, pain, nausea, eating disorders, several end points of Parkinson’s, and epilepsy in dogs and cats. IGC has assembled a portfolio of patent filings and four lead product candidates addressing these conditions. The company is based in Maryland, USA. For more information visit www.igcinc.us
About MissionIRNewsBreaks
MissionIRNewsBreaks provide a rapid summary of corporate news that catch the attention of MissionIR. MissionIRNewsBreaks are created by our Team of professional journalists that keep a constant eye on the markets, these posts are designed to inform you on the latest happenings of our clients and other publicly traded companies on our radar. From earnings, acquisitions and agreements to conference attendance and clinical study results, our news breaks keep you up-to-date with the day’s top movers. MissionIR is primarily focused on strategic communications. We have executed countless communications programs to address the needs of companies ranging from start-ups to established industry leaders, gaining valuable experience and the expertise necessary to determine the most effective strategy for any given situation.
MissionIR (MIR)
Atlanta, Georgia
www.MissionIR.com
404.941.8975 Office
Editor@MissionIR.com
Please see full terms of use and disclaimers on the Mission Investor Relations website applicable to all content provided by MIR, wherever published or re-published: http://www.missionir.com/disclaimer.html
To view the full press release, visit http://dtn.fm/vc40E
About IGC
IGC is engaged in the development of cannabis based combination therapies to treat Alzheimer’s, pain, nausea, eating disorders, several end points of Parkinson’s, and epilepsy in dogs and cats. IGC has assembled a portfolio of patent filings and four lead product candidates addressing these conditions. The company is based in Maryland, USA. For more information visit www.igcinc.us
About MissionIRNewsBreaks
MissionIRNewsBreaks provide a rapid summary of corporate news that catch the attention of MissionIR. MissionIRNewsBreaks are created by our Team of professional journalists that keep a constant eye on the markets, these posts are designed to inform you on the latest happenings of our clients and other publicly traded companies on our radar. From earnings, acquisitions and agreements to conference attendance and clinical study results, our news breaks keep you up-to-date with the day’s top movers. MissionIR is primarily focused on strategic communications. We have executed countless communications programs to address the needs of companies ranging from start-ups to established industry leaders, gaining valuable experience and the expertise necessary to determine the most effective strategy for any given situation.
MissionIR (MIR)
Atlanta, Georgia
www.MissionIR.com
404.941.8975 Office
Editor@MissionIR.com
Please see full terms of use and disclaimers on the Mission Investor Relations website applicable to all content provided by MIR, wherever published or re-published: http://www.missionir.com/disclaimer.html
Monday, October 16, 2017
Pressure BioSciences Inc. (PBIO) is “One to Watch”
- Poised to disrupt sciences sample preparation market estimated at $6 billion
- Nearly 300 patented enabling technology platform products installed at more than 150 sites worldwide
- Two patents awarded in China for Ultra Shear Technology used in wide range of industrial applications, including “clean foods”
- Finalist in prestigious 2017 R&D 100 Awards recognizing top revolutionary technologies
- Technology being used as part of the U.S. “Cancer Moonshot” initiative
Pressure BioSciences, Inc. (OTCQB: PBIO) develops, markets and sells proprietary laboratory instrumentation and associated consumables to the life sciences sample preparation market. Sample preparation refers to the wide range of activities that precede most forms of scientific analysis. It is often complex and time-consuming, yet a critical part of scientific research. The market for sample preparation products is currently estimated at $6 billion worldwide.
The Company’s product line can be used to exquisitely control the sample preparation process. It is based on a patented, enabling technology platform called pressure cycling technology (“PCT”). PCT uses alternating cycles of hydrostatic pressure between ambient (14.5 psi) and ultra-high levels (up to 100,000 psi) to safely and reproducibly control critical biological processes, such as the lysis (breakage) of cells, the digestion of proteins, and the inactivation of pathogens.
Pressure BioSciences’ product line is led by its newly released, next-generation Barocycler 2320EXTREME instrument. Named a finalist in the prestigious 2017 R&D Awards (also known as the “Oscars of Innovation”), the Barocycler 2320EXT is already being touted by some key opinion leaders as an essential element of the $1.8 billion U.S. “Cancer Moonshot” program. For example, Professor Phil Robinson, Co-head of the cancer research center of the Children’s Medical Research Institute (Sydney, Australia), said in a recent interview: “We are collecting the whole proteome on 70,000 tumor samples from all classes where complete clinical outcome is known. Due to its unique capabilities, the Barocycler 2320EXT has become a critical part of our program. It is the primary enabler of the high-throughput component of the project. Without this step, our project simply could not be done. In fact, the Barocycler 2320EXT works so well we have just purchased two more.”
Momentum is building when it comes to the potential for using the Company’s unique PCT technology platform. Leading scientists are intrigued by Pressure BioSciences’ approach, which among other attributes, revolutionizes the process of rupturing cells (lysis) for further study, yielding superior biomolecules for investigation. The Company’s technology transcends current methods of breaking open cells, which use chemicals, blades, metal beads, or other damaging and altering methods that can ultimately adversely affect the result for researchers. Pressure BioSciences’ PCT technology utilizes customized, controlled hydrostatic (water) pressure to rupture cells in a chamber, enabling exquisitely customized levels of pressure to optimally break open different types of cells at prescribed pressure levels—something never before accomplished in a commercial setting. Using this pioneering method, the result is a truer, more legitimate sample, which boosts the efficacy of research and the quality of results. The potential impact of this technology on scientific advancement is enormous, enabling research scientists to begin their studies with biological samples of unprecedented integrity, with the potential to improve research outcomes at the earliest, most critical step. PCT can additionally inactivate pathogens (e.g., viruses, bacteria) using hydrostatic pressure, making the samples safer to study—another innovation with astronomical potential for application in a variety of markets.
The Company’s high-pressure instruments for research purposes are marketed throughout the United States, Europe, China and Japan. To date, Pressure BioSciences has installed nearly 300 PCT Systems in over 165 leading academic, government, biotech and pharma laboratories around the world. Its primary applications are in biomarker discovery, forensics, agriculture and pathology. Over 100 scientific papers have been published on the advantages of the PCT platform, which is also being used in the specialized fields of drug discovery and design, bio-therapeutics characterization, soil and plant biology, vaccine development and histology.
Impressive as their biotech business is, there is more to the PBI story. Pressure BioSciences recently received two patents in China for its novel Ultra Shear Technology (UST), a process that has potential in a wide range of industrial applications, including extending the shelf life of some food products and making two insoluble liquids (like oil in water) soluble. Patents have also been filed in many other countries worldwide. UST is a novel technique based on the use of intense shear forces generated from ultra-high-pressure valve discharge.
This important technology has the potential to play a significant role in a number of commercially important areas through its ability to create high-quality, stable nanoemulsions. Scientific studies indicate that improved absorption, higher bioavailability, greater stability, lower surfactant levels and other advantages can be achieved with nanoemulsions – all hugely important factors in the fields of nutraceuticals, cosmetics, pharmaceuticals, and in various medical products. There is an enormous opportunity in the cannabis market, since the technology can potentially reduce oil droplets containing cannabidiol (CBD) to nanoparticles, after which they can be safely suspended in a stable water solution—something many companies have endeavored to achieve without success. Researchers looking for a way to increase the bioavailability of cannabinoids in the body will find this technology a game changer.
The Company’s UST technology also has possibilities in the production of clean label foods, which are currently processed using several innovative methods, including high-pressure treatments (such as Starbucks’ Evolution line of juices). In 2015, the worldwide market for high-pressure processed (HPP) food was estimated at U.S. $10 billion. UST uses ultra-high pressures and certain valves to generate intense shear forces under controlled temperature conditions to produce nanoemulsions, and which also significantly reduces food-borne pathogens. Pressure BioSciences’ initial focus with this technology will be to evaluate UST for the production of high-quality dairy products and beverages.
For more information, visit the company’s website at www.PressureBioSciences.com
About MissionIR
MissionIR is primarily focused on strategic communications. We have executed countless communications programs to address the needs of companies ranging from start-ups to established industry leaders, gaining valuable experience and the expertise necessary to determine the most effective strategy for any given situation.
For more information, visit www.MissionIR.com
MissionIR (MIR)
Atlanta, Georgia
www.MissionIR.com
404.941.8975 Office
Editor@MissionIR.com
Please see full terms of use and disclaimers on the Mission Investor Relations website applicable to all content provided by MIR, wherever published or re-published: http://www.missionir.com/disclaimer.html
Friday, October 13, 2017
Nevada Gold & Casinos, Inc. (NYSE: UWN) Improving Casino Odds
- Largest mini-casino operator in Washington
- Increasing revenues and profits
- Better odds than betting in a casino
Americans love casino gambling. In near record numbers, over 81 million people visited U.S. casinos in the 12-month period ended in the spring of 2017 (http://dtn.fm/jFUn2). From nickel slots to blackjack, almost everyone placed some form of wager, even though the house always has the edge. With such a penchant for casino gambling, the U.S. gaming industry is poised for another year of growth.
Blackjack has the best odds of winning, with a house edge of one to two percent in most casinos, notwithstanding the casino’s built-in advantage between the promised payout and the inherent odds of the game. The house never takes the extra risk; the bettor does. Popular slot machines have the lowest odds of winning, with a house edge of 10 percent or more. Despite the thrill and excitement, walking away a winner at a casino is a long shot. Rather than betting “in” casinos, better odds can be found betting “on” casinos. Well-run casinos are money pumps, and a more likely winning bet is buying a gaming company’s stock at the biggest casino of them all, the stock market.
Each year, gaming revenues in the U.S. yield more profits than the movie and recorded music industries combined. Even the combined revenue of the four major U.S. professional sports leagues is dwarfed by earnings from the commercial casinos industry. Casino stocks have surged this year with the big names leading the way. A smarter bet may be to look at smaller casino operators that enjoy similar ratios but haven’t made big moves yet.
Las Vegas-based Nevada Gold & Casinos, Inc. (NYSE MKT: UWN) is just such an operator. Nevada Gold & Casinos finances, develops, owns and operates gaming properties and projects in multiple U.S. locations. The company’s Washington Gold is the largest operator of mini-casinos in Washington. Nevada Gold also owns a slot route operation in Deadwood, South Dakota, and the Club Fortune Casino in Henderson, Nevada, with 540 slot machines, seven table games, a poker room, two bars, an entertainment lounge and a sports book. Washington’s mini-casinos have limited game options based on state law, but most offer multiple card games. Combined, Nevada Gold’s Washington facilities have over 120 table games including Blackjack, Pai Gow Poker, Baccarat, Spanish 21, Blackjack – Double Action, Ultimate Holdem, and Three and Four Card Poker. Additional banked table games are permitted along with poker and pull tabs. The company’s 24-hour Washington Gold casinos include full service restaurants with bars and collectively employ 1,100 people.
In July, Nevada Gold & Casinos announced financial results for the fourth quarter and year ended April 30, 2017 (http://dtn.fm/T63qV). For the fourth quarter of fiscal 2017, the company reported net revenues of $19.8 million and net income of $1.2 million, or $0.07 per share. For the fiscal year 2017, the company reported net revenues of $74.6 million, compared to $70.2 million in fiscal year 2016. The Board of Directors authorized a share repurchase program of $2.0 million in 2016 and completed the buy back at favorable prices. The Board has also approved an additional $2.0 million share buyback, a strong indication that the company believes it’s undervalued in the market.
Since the stock market’s recovery began in 2009, major gambling companies in the U.S. have beaten the broader market several fold. Expanding profit potential has triggered a rush within the gaming industry as companies buy up other players to capture as much market share as possible. This could bode well for Nevada Gold as a potentially attractive target. As a well-run profitable gaming company, Nevada Gold may also provide outsized returns of its own and deliver much better odds to pocket casino cash.
For more information, visit the company’s website at www.NevadaGold.com
About MissionIR
MissionIR is primarily focused on strategic communications. We have executed countless communications programs to address the needs of companies ranging from start-ups to established industry leaders, gaining valuable experience and the expertise necessary to determine the most effective strategy for any given situation.
For more information, visit www.MissionIR.com
MissionIR (MIR)
Atlanta, Georgia
www.MissionIR.com
404.941.8975 Office
Editor@MissionIR.com
Please see full terms of use and disclaimers on the Mission Investor Relations website applicable to all content provided by MIR, wherever published or re-published: http://www.missionir.com/disclaimer.html
MissionIRNewsBreaks – India Globalization Capital (NYSE: IGC) Achieves Breakthrough with Potential to Prevent, Combat Alzheimer’s
India Globalization Capital (NYSE MKT: IGC), a first mover in the cannabis-based combination therapy space, recently announced that it is readying a line of cannabis-based medical dispensary products that target Alzheimer’s disease (http://dtn.fm/tQo00). IGC is engineering genetic cell lines which demonstrate that, at various concentrations of tetrahydrocannabinol (THC), the protein Aβ decreases as much as 40 percent without neuron damage. An article discussing this reads: “This compelling in vitro data, and the promise it shows as a preventative and powerful treatment against Alzheimer’s, makes IGC a company with valuation growth potential for investors. The commercial potential for an Alzheimer’s treatment or prevention drug is in the billions of dollars. Investors have made Alzheimer’s drugs a high biotechnology priority.”
To view the full article, visit http://dtn.fm/8w3OJ
About IGC
IGC is engaged in the development of cannabis based combination therapies to treat Alzheimer’s, pain, nausea, eating disorders, several end points of Parkinson’s, and epilepsy in dogs and cats. IGC has assembled a portfolio of patent filings and four lead product candidates addressing these conditions. The company is based in Maryland, USA. For more information please visit www.igcinc.us
About MissionIRNewsBreaks
MissionIRNewsBreaks provide a rapid summary of corporate news that catch the attention of MissionIR. MissionIRNewsBreaks are created by our Team of professional journalists that keep a constant eye on the markets, these posts are designed to inform you on the latest happenings of our clients and other publicly traded companies on our radar. From earnings, acquisitions and agreements to conference attendance and clinical study results, our news breaks keep you up-to-date with the day’s top movers. MissionIR is primarily focused on strategic communications. We have executed countless communications programs to address the needs of companies ranging from start-ups to established industry leaders, gaining valuable experience and the expertise necessary to determine the most effective strategy for any given situation.
MissionIR (MIR)
Atlanta, Georgia
www.MissionIR.com
404.941.8975 Office
Editor@MissionIR.com
Please see full terms of use and disclaimers on the Mission Investor Relations website applicable to all content provided by MIR, wherever published or re-published: http://www.missionir.com/disclaimer.html
To view the full article, visit http://dtn.fm/8w3OJ
About IGC
IGC is engaged in the development of cannabis based combination therapies to treat Alzheimer’s, pain, nausea, eating disorders, several end points of Parkinson’s, and epilepsy in dogs and cats. IGC has assembled a portfolio of patent filings and four lead product candidates addressing these conditions. The company is based in Maryland, USA. For more information please visit www.igcinc.us
About MissionIRNewsBreaks
MissionIRNewsBreaks provide a rapid summary of corporate news that catch the attention of MissionIR. MissionIRNewsBreaks are created by our Team of professional journalists that keep a constant eye on the markets, these posts are designed to inform you on the latest happenings of our clients and other publicly traded companies on our radar. From earnings, acquisitions and agreements to conference attendance and clinical study results, our news breaks keep you up-to-date with the day’s top movers. MissionIR is primarily focused on strategic communications. We have executed countless communications programs to address the needs of companies ranging from start-ups to established industry leaders, gaining valuable experience and the expertise necessary to determine the most effective strategy for any given situation.
MissionIR (MIR)
Atlanta, Georgia
www.MissionIR.com
404.941.8975 Office
Editor@MissionIR.com
Please see full terms of use and disclaimers on the Mission Investor Relations website applicable to all content provided by MIR, wherever published or re-published: http://www.missionir.com/disclaimer.html
Thursday, October 12, 2017
Moxian, Inc. (NASDAQ: MOXC) Positioned to Exploit China’s Consumer Consumption Growth
- China will see nearly $2 trillion in new consumer-driven consumption by 2021
- Moxian facilitates Chinese consumer consumption
- Tweaked business model positions Moxian for more rapid expansion
China’s overall economic growth has slowed from its nearly 30 years of 10 percent annual improvement, but the Chinese consumer economy is still massive in absolute terms and poised for steadily increased expansion. With a population of 1.3 billion, China now comprises the world’s second-largest economy. Since the market reforms in 1978, China has shifted from a central government planned economy to a market-based economy and has experienced rapid consumer-driven economic development. China is now an upper middle-income country that sustains a targeted 6.5 percent GDP growth rate and has lifted nearly a billion people out of poverty. From centrally planned to consumer-driven, China’s growth is now consumer reliant.
China will see nearly $2 trillion in new consumer-driven consumption by 2021, which equates to about 27 percent of “total consumption growth” that will occur in the world’s major economies during the same period (http://dtn.fm/p4EEb). Over the next several years, China will prove to be one of the greatest opportunities in the world for consumer-oriented companies.
Technology is stoking China’s consumer growth. Skipping historic hard wired infrastructure, the Chinese consumer is mobile and internet savvy. About twice the percentage of Chinese consumers are likely to use a mobile device to make retail purchases as their counterparts in Europe and the United States.
Recently upgrading its mobile payments capability, Moxian, Inc. (NASDAQ: MOXC) is bridging e-commerce to brick and mortar retail. Moxian’s creative and socially interactive online platforms and mobile applications are moving the Chinese consumer from online views to retail purchases at Moxian’s brick and mortar client locations. The company’s seductive social network integrates social media and business into a single platform that offers products, features and services that appeal to consumers, keeping them engaged and referring new customers.
The company’s ingenious and captivating online platforms and mobile applications, the Moxian+ User app and the Moxian+ Business app, allow businesses to interface with both new and existing customers. These online interactions provide each business with the data to analyze consumer likes, dislikes and trends. Moxian’s platforms provide businesses with the ability to create, manage and promote individualized customer loyalty programs, targeted advertising campaigns and special promotions. These interactions between users and Moxian’s merchant clients drive retail traffic into the brick and mortar locations and give merchant client the ability to study consumer behavior and custom-tailor offerings to consumers.
To exploit the immense upside trend, Moxian recently tweaked its business model to grow even more rapidly by utilizing a joint venture strategy and leveraging entrenched businesses to efficiently penetrate China’s top four markets. MOXC’s relationship with China’s dominant payment processor, UnionPay, is integral to the new strategy. A UnionPay processing module on the Moxian+ platform allows MOXC to attract new joint venture partners in China and neighboring Asian markets. The Moxian+ Merchant platform now offers digital processing modules for UnionPay, Alipay, and WeChatPay. These modules allow payment processing as Moxian drives evermore traffic and engages evermore consumers. These changes place Moxian even more in the mix and poised to reap substantial rewards by facilitating the immense growth of the Chinese consumer market.
For more information, visit the company’s website at www.Moxian.com
About MissionIR
MissionIR is primarily focused on strategic communications. We have executed countless communications programs to address the needs of companies ranging from start-ups to established industry leaders, gaining valuable experience and the expertise necessary to determine the most effective strategy for any given situation.
For more information, visit www.MissionIR.com
MissionIR (MIR)
Atlanta, Georgia
www.MissionIR.com
404.941.8975 Office
Editor@MissionIR.com
Please see full terms of use and disclaimers on the Mission Investor Relations website applicable to all content provided by MIR, wherever published or re-published: http://www.missionir.com/disclaimer.html
Wednesday, October 11, 2017
Standard Lithium Ltd. (TSX.V: SLL) (FRA: S5L) (OTCQX: STLHF) Expands Lithium Mining Project
- STLHF adds 6,000 more acres to its Bristol Dry Lake Lithium Project, and aims to be a significant low-cost, domestic producer of battery-grade lithium materials
- Electric cars and smart phones use ion-lithium rechargeable batteries — driving prices and demand. According to Platt’s, lithium production can be expected to grow to 500,000 metric tons by 2020 from 200,000 today
- Goldman Sachs terms lithium “the new gasoline” as it projects that electric cars will have 61% market penetration by 2040, when it sees sales of electric cars outnumbering gasoline units
Standard Lithium Ltd. (TSX.V: SLL) (FRA: S5L) (OTCQX: STLHF) is part of a worldwide race to produce enough lithium to satisfy the growing demand for the ore from electric car makers and smart phone makers. The question now is how soon miners can bring their lithium supply online to meet that demand. Companies such as Tesla have an insatiable demand for lithium, with Platt’s projecting that production could grow to 500,000 metric tons by 2020 from 200,000 today (http://dtn.fm/0wIWS).
STLHF is a junior lithium mining company with a market cap of only $62 million. Along with others, it is aggressively seeking to fill increased worldwide demand for lithium for the manufacture of lithium-ion batteries used in the manufacture of electric cars and smart phones. Goldman Sachs has termed lithium as “the new gasoline”, according to an article titled, “The Global Scramble For Lithium” (http://dtn.fm/Ze2yY). STLHF is focused on finding more lithium in the Bristol Dry Lake project to boost its valuation for investors as a significant low-cost, domestic producer of battery-grade lithium materials.
While Australia, Chile and China are top producers of lithium globally, according to Lithium Investing News (http://dtn.fm/5M5lO), STLHF has announced that its subsidiary, California Lithium Ltd., has signed an amendment agreement with National Chloride Company of America to expand its land production lease in California (http://dtn.fm/4SujJ). The U.S. is only the eighth-ranked lithium producer worldwide. According to the U.S. Geological Survey, “The U.S. has a lot more untapped lithium resources than economically mined reserves at this point” (Feb, 2017). Standard Lithium believes significant opportunity exists to develop geopolitically secure domestic U.S. lithium assets. The amended agreement adds 6,000 acres to STLHF’s land holdings in the Bristol Dry Lake Lithium Project, now totaling 25,000 acres in the Mojave region of San Bernardino County in California.
Lithium Investing News reports that lithium production rose 12% in 2016 to 35,000 metric tons. Morgan Stanley projects that more electric cars will be sold by 2040 than gas-powered cars, with market penetration growing from 16% in 2030 to 51% by 2040 (http://dtn.fm/w9RyQ). In its most bullish scenario, projections are that electric cars will reach 60% market penetration by 2040 and 90% by 2045. Whichever projection comes true, 159,000 more electric vehicles were on the road in 2016, and sales were up 38% over 2015 levels, according to research from FleetCarma (http://dtn.fm/aFHJ8).
For more information, visit the company’s website at www.StandardLithium.com
About MissionIR
MissionIR is primarily focused on strategic communications. We have executed countless communications programs to address the needs of companies ranging from start-ups to established industry leaders, gaining valuable experience and the expertise necessary to determine the most effective strategy for any given situation.
For more information, visit www.MissionIR.com
MissionIR (MIR)
Atlanta, Georgia
www.MissionIR.com
404.941.8975 Office
Editor@MissionIR.com
Please see full terms of use and disclaimers on the Mission Investor Relations website applicable to all content provided by MIR, wherever published or re-published: http://www.missionir.com/disclaimer.html
MissionIRNewsBreaks – Emblem Corp. (TSX.V: EMC) (OTC: EMMBF) Sharpens Focus on Potentially Game-Changing Sustained Release Cannabinoid Formulation
Licensed Canadian cannabis cultivation company Emblem Corp. (TSX.V: EMC) (OTC: EMMBF) recently entered into a collaboration and licensing agreement with Canntab Therapeutics Limited to collaborate on the preclinical formulation, clinical development, regulatory approval, manufacturing and commercialization of Canntab’s patent-pending oral sustained release cannabinoid formulation. The agreement grants Emblem the exclusive right to Canntab’s patents and expertise in Canada to develop, commercialize, use, sell and offer—but not import or export—the product, which will be sold under the Emblem brand. An article discussing this reads: “For pharmaceutical ingredients that are typically short-acting, like cannabinoids, sustained release formulations enable dosage schedules that are more convenient, offer longer action duration and are better accepted by health care professionals and patients. The patent-pending extended release formulation being collaboratively developed by Emblem and Canntab will enable medical professionals, for the first time, to establish proper dosages for patients and will, for the patients, make it easier to take medical cannabis. Emblem believes the development of advanced dosage forms, and the pharmacokinetic and clinical research associated with this development, will effectively advance cannabinoid therapy. The company also anticipates that introducing sustained release cannabinoid formulations that are easily titratable will significantly increase the market for cannabinoid-based medications—especially for the treatment of conditions like chronic neuropathic pain.”
To view the full article, visit http://dtn.fm/9k9NF
About Emblem
Emblem is licensed under the Access to Cannabis for Medical Purposes Regulations (the “ACMPR”) to cultivate and sell medical marihuana. Emblem carries out its principal activities producing marihuana from its facilities in Paris, Ontario pursuant to the provisions of the ACMPR and the Controlled Drugs and Substances Act (Canada) and its regulations. For more information, visit the company’s website at www.emblemcorp.com
About MissionIRNewsBreaks
MissionIRNewsBreaks provide a rapid summary of corporate news that catch the attention of MissionIR. MissionIRNewsBreaks are created by our Team of professional journalists that keep a constant eye on the markets, these posts are designed to inform you on the latest happenings of our clients and other publicly traded companies on our radar. From earnings, acquisitions and agreements to conference attendance and clinical study results, our news breaks keep you up-to-date with the day’s top movers. MissionIR is primarily focused on strategic communications. We have executed countless communications programs to address the needs of companies ranging from start-ups to established industry leaders, gaining valuable experience and the expertise necessary to determine the most effective strategy for any given situation.
MissionIR (MIR)
Atlanta, Georgia
www.MissionIR.com
404.941.8975 Office
Editor@MissionIR.com
Please see full terms of use and disclaimers on the Mission Investor Relations website applicable to all content provided by MIR, wherever published or re-published: http://www.missionir.com/disclaimer.html
To view the full article, visit http://dtn.fm/9k9NF
About Emblem
Emblem is licensed under the Access to Cannabis for Medical Purposes Regulations (the “ACMPR”) to cultivate and sell medical marihuana. Emblem carries out its principal activities producing marihuana from its facilities in Paris, Ontario pursuant to the provisions of the ACMPR and the Controlled Drugs and Substances Act (Canada) and its regulations. For more information, visit the company’s website at www.emblemcorp.com
About MissionIRNewsBreaks
MissionIRNewsBreaks provide a rapid summary of corporate news that catch the attention of MissionIR. MissionIRNewsBreaks are created by our Team of professional journalists that keep a constant eye on the markets, these posts are designed to inform you on the latest happenings of our clients and other publicly traded companies on our radar. From earnings, acquisitions and agreements to conference attendance and clinical study results, our news breaks keep you up-to-date with the day’s top movers. MissionIR is primarily focused on strategic communications. We have executed countless communications programs to address the needs of companies ranging from start-ups to established industry leaders, gaining valuable experience and the expertise necessary to determine the most effective strategy for any given situation.
MissionIR (MIR)
Atlanta, Georgia
www.MissionIR.com
404.941.8975 Office
Editor@MissionIR.com
Please see full terms of use and disclaimers on the Mission Investor Relations website applicable to all content provided by MIR, wherever published or re-published: http://www.missionir.com/disclaimer.html
India Globalization Capital (NYSE: IGC) Announces Significant Breakthrough that Could Potentially Prevent, Fight Alzheimer’s Disease
- Seeks patent on new therapy for drug that employs concentrations of THC
- Data for drug candidate IGC-AD1 finds that it reduces buildup of ‘senior plaque’ without causing death of neurons, which can lead to memory loss
- IGC plans to commercialize drug as a supplement to be marketed as a medical dispensary product
India Globalization Capital (NYSE MKT: IGC) recently announced that it is assembling a line of cannabis-based medical dispensary products targeting Alzheimer’s disease (http://dtn.fm/Rcl69). The company is engineering genetic cell lines which show that, at various concentrations of THC, the protein Aβ decreases as much as 40% without neuron damage.
This compelling in vitro data, and the promise it shows as a preventative and powerful treatment against Alzheimer’s, makes IGC a company with valuation growth potential for investors. The commercial potential for an Alzheimer’s treatment or prevention drug is in the billions of dollars. Investors have made Alzheimer’s drugs a high biotechnology priority.
IGC is a first-mover in the cannabis-based combination therapy space. The Bethesda, Maryland-based company has already filed for six patents in the markets of epilepsy, eating disorders and pain. It is also working on additional filings for indications including depression, Alzheimer’s disease, post-traumatic stress disorder and Parkinson’s disease.
“As Alzheimer’s progresses, synaptic dysfunction and the death of neurons lead to memory loss,” IGC CEO Ram Mukunda stated in a news release. “These study results, when combined with the earlier reported data that shows IGC-AD1 reduces Aβ40 and Aβ42 production by as much as 50% and 40%, without any toxicity, represent a highly significant novel breakthrough that could potentially bring much needed relief from this devastating disease.”
It is believed that a primary cause of Alzheimer’s disease is the buildup of senile plaque, or Aβ plaque, in the cerebral cortex and hippocampus. As the disease progresses, Aβ oligomers directly cause synaptic dysfunction and the death of neurons, leading to memory loss.
“In vitro, our product demonstrates these critical factors and we are pursuing a patent filing that protects this therapy,” Mukunda added.
IGC has a two-step plan. First, it will position IGC-AD1 both as a treatment and a preventative therapy for Alzheimer’s. Second, IGC plans to commercialize a supplement version of the drug to be sold as a medical dispensary product.
Alzheimer’s affects more than 5.3 million Americans, and more than 65% of the patients suffering from the disease are women. It is known as America’s most expensive disease, costing the economy an estimated $236 billion. Over the next 20 years, the number of people with the disease is expected to double. Alzheimer’s begins 20-25 years prior to clear symptoms. To date, no effective cure has been found.
For more information, visit the company’s website at www.IGCInc.us
About MissionIR
MissionIR is primarily focused on strategic communications. We have executed countless communications programs to address the needs of companies ranging from start-ups to established industry leaders, gaining valuable experience and the expertise necessary to determine the most effective strategy for any given situation.
For more information, visit www.MissionIR.com
MissionIR (MIR)
Atlanta, Georgia
www.MissionIR.com
404.941.8975 Office
Editor@MissionIR.com
Please see full terms of use and disclaimers on the Mission Investor Relations website applicable to all content provided by MIR, wherever published or re-published: http://www.missionir.com/disclaimer.html
Tuesday, October 10, 2017
MissionIRNewsBreaks – Standard Lithium Ltd. (TSX.V: SLL) (FRA: S5L) (OTCQX: STLHF) Issues Update on Bristol Dry Lake Exploration
Canadian energy exploration and development company Standard Lithium Ltd. (TSX.V: SLL) (FRA: S5L) (OTCQX: STLHF) this morning offered an update on its exploration and process testing program at its Bristol Dry Lake lithium brine projected located in California’s Mojave Desert. Per the release, the company has commenced a resource definition drill program on the project with the objective of establishing the lithium grade of the subsurface brine across the extensive landholdings. The program also aims to determine the depth and lateral extent of the brine and to define key geological and hydrogeological data, as needed to develop a maiden resource estimate. “Standard’s exploration and process-testing programs are now fully underway and being completed in parallel by our highly experienced resource assessment and chemical engineering teams,” Andy Robinson, president and COO of Standard Lithium, stated in the news release. “The amount of work that we’ve been able to complete in such a short period of time is evidence of our fast-track development philosophy, and speaks volumes to the constructive relationships that we have in place with the existing fully-permitted brine producers in operation at Bristol Dry Lake. All of the work being completed right now will be used to support the maiden 43-101 resource estimate for the Bristol Dry Lake lithium brine project, estimated for the first half of 2018.”
To view the full press release, visit http://dtn.fm/2zE4F
About Standard Lithium
Standard’s value creation strategy encompasses acquiring a diverse and highly prospective portfolio of large-scale domestic brine resources, led by an innovative and results-oriented management team with a strong focus on technical skills. The Company is currently focused on the immediate exploration and development of the Bristol Dry Lake Lithium Project located in the Mojave region of San Bernardino County, California; the location has significant infrastructure in-place, with easy road and rail access, abundant electricity and water sources, and is already permitted for extensive brine extraction and processing activities. The Company is also commencing due diligence and resource evaluation on 33,000 acres of lithium brine leases located in the Smackover Formation. For more information, visit the company’s website at www.standardlithium.com
About MissionIRNewsBreaks
MissionIRNewsBreaks provide a rapid summary of corporate news that catch the attention of MissionIR. MissionIRNewsBreaks are created by our Team of professional journalists that keep a constant eye on the markets, these posts are designed to inform you on the latest happenings of our clients and other publicly traded companies on our radar. From earnings, acquisitions and agreements to conference attendance and clinical study results, our news breaks keep you up-to-date with the day’s top movers. MissionIR is primarily focused on strategic communications. We have executed countless communications programs to address the needs of companies ranging from start-ups to established industry leaders, gaining valuable experience and the expertise necessary to determine the most effective strategy for any given situation.
MissionIR (MIR)
Atlanta, Georgia
www.MissionIR.com
404.941.8975 Office
Editor@MissionIR.com
Please see full terms of use and disclaimers on the Mission Investor Relations website applicable to all content provided by MIR, wherever published or re-published: http://www.missionir.com/disclaimer.html
To view the full press release, visit http://dtn.fm/2zE4F
About Standard Lithium
Standard’s value creation strategy encompasses acquiring a diverse and highly prospective portfolio of large-scale domestic brine resources, led by an innovative and results-oriented management team with a strong focus on technical skills. The Company is currently focused on the immediate exploration and development of the Bristol Dry Lake Lithium Project located in the Mojave region of San Bernardino County, California; the location has significant infrastructure in-place, with easy road and rail access, abundant electricity and water sources, and is already permitted for extensive brine extraction and processing activities. The Company is also commencing due diligence and resource evaluation on 33,000 acres of lithium brine leases located in the Smackover Formation. For more information, visit the company’s website at www.standardlithium.com
About MissionIRNewsBreaks
MissionIRNewsBreaks provide a rapid summary of corporate news that catch the attention of MissionIR. MissionIRNewsBreaks are created by our Team of professional journalists that keep a constant eye on the markets, these posts are designed to inform you on the latest happenings of our clients and other publicly traded companies on our radar. From earnings, acquisitions and agreements to conference attendance and clinical study results, our news breaks keep you up-to-date with the day’s top movers. MissionIR is primarily focused on strategic communications. We have executed countless communications programs to address the needs of companies ranging from start-ups to established industry leaders, gaining valuable experience and the expertise necessary to determine the most effective strategy for any given situation.
MissionIR (MIR)
Atlanta, Georgia
www.MissionIR.com
404.941.8975 Office
Editor@MissionIR.com
Please see full terms of use and disclaimers on the Mission Investor Relations website applicable to all content provided by MIR, wherever published or re-published: http://www.missionir.com/disclaimer.html
Thursday, October 5, 2017
MissionIRNewsBreaks – Net Element, Inc. (NASDAQ: NETE) Subsidiary to Exhibit at Florida Restaurant & Lodging Show
Global financial technology and value-added solutions group Net Element, Inc. (NASDAQ: NETE) this morning announced that its Aptito subsidiary will exhibit at the 2017 Florida Restaurant & Lodging Show scheduled to take place from October 11-13 at the Orange County Convention Center in Orlando, Florida. The event is expected to provide Aptito with added exposure as it unveils its most comprehensive Restaurant POS placement program to the market. “We are very excited to showcase our Aptito POS solution and kick off our North America road show to present our solution to merchants across the United States,” Vlad Sadovskiy, President of Integrated Payments for Net Element, stated in the news release. “Our simple all inclusive EMV POS offering and comprehensive features are sure to streamline operations at any restaurant.”
This morning’s update comes just a day after Net Element announced a one-for-ten reverse stock split of its common stock, effective today (http://dtn.fm/p9sJE). The reverse split, which reduced the company’s total number of outstanding shares from approximately 22 million to roughly 2.2 million, is intended to increase Net Element’s price per share in order to satisfy the $1.00 minimum bid price requirement for continued listing on the Nasdaq Capital Market.
To view the full press release, visit http://dtn.fm/2Ci4f
About Net Element
Net Element, Inc. (NASDAQ: NETE) operates a payments-as-a-service transactional and value-added services platform for small to medium enterprise (“SME”) in the US and selected emerging markets. In the US it aims to grow transactional revenue by innovating SME productivity services such as its cloud based, restaurant and retail point-of-sale solution Aptito. Internationally, Net Element’s strategy is to leverage its omni-channel platform to deliver flexible offerings to emerging markets with diverse banking, regulatory and demographic conditions such as UAE, Kazakhstan, Kyrgyzstan and Azerbaijan where initiatives have been recently launched. Net Element was named in 2016 by South Florida Business Journal as one of the fastest growing technology companies. Further information is available at www.netelement.com.
About MissionIRNewsBreaks
MissionIRNewsBreaks provide a rapid summary of corporate news that catch the attention of MissionIR. MissionIRNewsBreaks are created by our Team of professional journalists that keep a constant eye on the markets, these posts are designed to inform you on the latest happenings of our clients and other publicly traded companies on our radar. From earnings, acquisitions and agreements to conference attendance and clinical study results, our news breaks keep you up-to-date with the day’s top movers. MissionIR is primarily focused on strategic communications. We have executed countless communications programs to address the needs of companies ranging from start-ups to established industry leaders, gaining valuable experience and the expertise necessary to determine the most effective strategy for any given situation.
MissionIR (MIR)
Atlanta, Georgia
www.MissionIR.com
404.941.8975 Office
Editor@MissionIR.com
Please see full terms of use and disclaimers on the Mission Investor Relations website applicable to all content provided by MIR, wherever published or re-published: http://www.missionir.com/disclaimer.html
This morning’s update comes just a day after Net Element announced a one-for-ten reverse stock split of its common stock, effective today (http://dtn.fm/p9sJE). The reverse split, which reduced the company’s total number of outstanding shares from approximately 22 million to roughly 2.2 million, is intended to increase Net Element’s price per share in order to satisfy the $1.00 minimum bid price requirement for continued listing on the Nasdaq Capital Market.
To view the full press release, visit http://dtn.fm/2Ci4f
About Net Element
Net Element, Inc. (NASDAQ: NETE) operates a payments-as-a-service transactional and value-added services platform for small to medium enterprise (“SME”) in the US and selected emerging markets. In the US it aims to grow transactional revenue by innovating SME productivity services such as its cloud based, restaurant and retail point-of-sale solution Aptito. Internationally, Net Element’s strategy is to leverage its omni-channel platform to deliver flexible offerings to emerging markets with diverse banking, regulatory and demographic conditions such as UAE, Kazakhstan, Kyrgyzstan and Azerbaijan where initiatives have been recently launched. Net Element was named in 2016 by South Florida Business Journal as one of the fastest growing technology companies. Further information is available at www.netelement.com.
About MissionIRNewsBreaks
MissionIRNewsBreaks provide a rapid summary of corporate news that catch the attention of MissionIR. MissionIRNewsBreaks are created by our Team of professional journalists that keep a constant eye on the markets, these posts are designed to inform you on the latest happenings of our clients and other publicly traded companies on our radar. From earnings, acquisitions and agreements to conference attendance and clinical study results, our news breaks keep you up-to-date with the day’s top movers. MissionIR is primarily focused on strategic communications. We have executed countless communications programs to address the needs of companies ranging from start-ups to established industry leaders, gaining valuable experience and the expertise necessary to determine the most effective strategy for any given situation.
MissionIR (MIR)
Atlanta, Georgia
www.MissionIR.com
404.941.8975 Office
Editor@MissionIR.com
Please see full terms of use and disclaimers on the Mission Investor Relations website applicable to all content provided by MIR, wherever published or re-published: http://www.missionir.com/disclaimer.html
Wednesday, October 4, 2017
Moxian, Inc.’s (NASDAQ: MOXC) Relationship with UnionPay Key to Joint Venture Market Penetration Strategy in China
- UnionPay module in Moxian+ User and Moxian+ Business apps gives access for potential joint venture partners to China’s largest payment processor
- Hao Qing Hu named as new company president and CEO in addition to Moxian director
- Seven directors elected to Moxian’s board at annual meeting, including Shewn International Group CEO Ms. Liu Shu Juan
Moxian, Inc. (NASDAQ: MOXC) has a key ingredient to attract joint venture partners in its growth strategy in China: the UnionPay module in its new User and Business apps. UnionPay is the largest payment processor in China and owns 25% of the global market for credit cards, third only to Visa and MasterCard (http://dtn.fm/dKz6h). It also has a presence in more than 160 countries worldwide, including the U.S.
Moxian is an integrated social media platform operator, striving to convert its unpaid Moxian+ Business and Moxian+ User platforms to paid within the online-to-offline (O2O) market in China. It connects users to merchant clients through games, rewards and social events. It offers Mo-Coin and Mo-Point reward systems.
MOXC’s special relationship to UnionPay gives businesses and vendors in China access to the largest payment processor in the country. MOXC has a new growth strategy employing partners to help it expand into more Chinese cities quicker and with lower costs. It signed an agreement in principal for its first joint venture partner, Shewn International Group of Shanghai, a successful marketer of fine wines in China. UnionPay makes MOXC a desirable partner for Shewn.
Crystal Equity Research LLC projects that Moxian will generate sales of $2.3 million in FY2018, in part from the new revenue stream of receiving a fee of 1% of all Shewn payments processed on Moxian’s UnionPay app (http://dtn.fm/76hJy). Crystal Equity Research also noted that Moxian has reduced its spending to $1.3 million for the quarter ended June 2017, down from the $5.4 million it spent in the prior quarter due to reduced selling, general and administrative (SG&A) expenses. Crystal Equity Research said it anticipates raising its projections for Moxian’s revenues after the Shewn joint venture is executed.
At the company’s annual meeting, Hao Qing Hu was named the company’s president and CEO and also elected as a director of the company. He has been a director of Moxian since January 2016 and, since September 2015, has been the general manager of subsidiary Moxian Beijing, maintaining responsibility for all operations.
Additionally, Ms. Liu Shu Juan was elected director. She is CEO of Shewn International Group and financial controller of Shanghai Shewn Co., Ltd., the company’s primary operator in China.
For more information, visit the company’s website at www.Moxian.com
About MissionIR
MissionIR is primarily focused on strategic communications. We have executed countless communications programs to address the needs of companies ranging from start-ups to established industry leaders, gaining valuable experience and the expertise necessary to determine the most effective strategy for any given situation.
For more information, visit www.MissionIR.com
MissionIR (MIR)
Atlanta, Georgia
www.MissionIR.com
404.941.8975 Office
Editor@MissionIR.com
Please see full terms of use and disclaimers on the Mission Investor Relations website applicable to all content provided by MIR, wherever published or re-published: http://www.missionir.com/disclaimer.html
Standard Lithium Ltd. (TSX.V: SLL) (FRA: S5L) (OTCQX: STLHF) is “One to Watch”
- Exploration of Bristol Lake Project reveals excellent lithium-bearing brine harvest potential
- Global lithium compounds market projected to reach U.S. $5.87 billion by 2020
- Technological advances provide access to low cost, battery-grade lithium materials
- World demand for lithium expected to increase 300% by 2025
Standard Lithium Ltd. (TSX.V: SLL) (FRA: S5L) (OTCQX: STLHF) is a Canadian-based energy exploration and development company that is building one of the largest portfolios of high quality, domestic U.S. lithium brine assets. Its data and technology driven project development model is grounded in knowledge, opportunity and speed. Standard Lithium is led by an innovative and results-oriented management team with a strong focus on technical skills. The company has acquired several prospective lithium brine projects with known geological values consistent with producing basins, including its primary focus, the Bristol Dry Lake, California brownfield project that is permitted for related mineral production with accompanying world class infrastructure which are expected to contribute to faster, lower cost exploration and commercial development programs.
Recent results from a geophysical survey of the 25,000-acre Bristol Lake site suggest a high concentration of lithium-bearing brines are present throughout the company’s mineral lease agreement claims. Standard Lithium’s strategic partner in the venture, National Chloride Corporation of America, is well established in the region. All necessary infrastructure is on site, which gives Standard Lithium immediate access to conduct exploration brine sampling, lithium extraction, evaporation and processing activities, all within a fast-track project development schedule.
World demand for lithium continues to surge. The global lithium compounds market is projected to reach U.S. $5.87 billion by 2020, at a compound annual growth rate of 13.22% between 2015 and 2020. Lithium-ion batteries are the fastest growing segment of the market.
Standard Lithium’s determination to provide battery-grade lithium materials is bolstered by its recently appointed Scientific Advisory Council. These leading lithium extraction scientists and process engineers will oversee and direct the necessary lithium extraction process testing work. In addition to the Bristol Lake Brine Project, the company signed a Memorandum of Understanding in August with an unnamed New York Stock Exchange-listed company on an option for Standard to acquire lithium exploration and productions rights on 30,000 net brine acres overlying the Smackover formation in a region with a history of commercial-scale brine processing. Management believes lithium-bearing brines are likely present in this area. Smackover brines are metal-rich brine anomalies in reservoir rocks along the Gulf Coast from east Texas to Florida known to be a prime lithium resource. This resource may be one of the most promising ones to develop, given that a large-scale brine extraction, processing and reinjection industry is already well established.
Recently, Standard Lithium closed a multi-million dollar private placement offering, which allows the company to advance its current projects and pursue strategic acquisitions in the lithium sector. The company is well positioned with significant exploration opportunities featuring low cost production costs, easy transport, proximity to demand, and access to innovative production methodology.
For more information, visit the company’s website at www.StandardLithium.com
About MissionIR
MissionIR is primarily focused on strategic communications. We have executed countless communications programs to address the needs of companies ranging from start-ups to established industry leaders, gaining valuable experience and the expertise necessary to determine the most effective strategy for any given situation.
For more information, visit www.MissionIR.com
MissionIR (MIR)
Atlanta, Georgia
www.MissionIR.com
404.941.8975 Office
Editor@MissionIR.com
Please see full terms of use and disclaimers on the Mission Investor Relations website applicable to all content provided by MIR, wherever published or re-published: http://www.missionir.com/disclaimer.html
MissionIRNewsBreaks – India Globalization Capital, Inc. (NYSE: IGC) Provides Update on In Vitro Data Related to IGC-AD1
India Globalization Capital, Inc. (NYSE American: IGC), a developer of cannabis-based therapies to treat a variety of life-altering conditions, this morning provided an update on compelling in vitro data compiled from genetically engineered cell lines within an Alzheimer’s disease model showing that, at varying concentrations of IGC-AD1, mitochondrial function is enhanced by 30-60 percent. “Based on our analysis of this and other previously announced compelling data, we are readying IGC-AD1 in a liquid formulation that will not cause inebriation,” Ram Mukunda, CEO of IGC, stated in the news release. “The initial commercialization will be through licensed medical cannabis dispensaries.” As noted in this morning’s update, mitochondrial dysfunction is believed to be at the apex of the Alzheimer’s pyramid, making it responsible for triggering a cascade of symptoms resulting in the devastating condition. As such, IGC-AD1’s ability to improve mitochondrial function could serve as a significant breakthrough in the treatment of Alzheimer’s, which is noted as America’s most expensive disease with its estimated annual cost of $236 billion.
To view the full press release, visit http://dtn.fm/MyB72
About IGC
IGC is engaged in the development of cannabis based combination therapies to treat Alzheimer’s, pain, nausea, eating disorders, several end points of Parkinson’s, and epilepsy in dogs and cats. IGC has assembled a portfolio of patent filings and four lead product candidates addressing these conditions. The company is based in Maryland, USA. For more information visit www.igcinc.us
About MissionIRNewsBreaks
MissionIRNewsBreaks provide a rapid summary of corporate news that catch the attention of MissionIR. MissionIRNewsBreaks are created by our Team of professional journalists that keep a constant eye on the markets, these posts are designed to inform you on the latest happenings of our clients and other publicly traded companies on our radar. From earnings, acquisitions and agreements to conference attendance and clinical study results, our news breaks keep you up-to-date with the day’s top movers. MissionIR is primarily focused on strategic communications. We have executed countless communications programs to address the needs of companies ranging from start-ups to established industry leaders, gaining valuable experience and the expertise necessary to determine the most effective strategy for any given situation.
MissionIR (MIR)
Atlanta, Georgia
www.MissionIR.com
404.941.8975 Office
Editor@MissionIR.com
Please see full terms of use and disclaimers on the Mission Investor Relations website applicable to all content provided by MIR, wherever published or re-published: http://www.missionir.com/disclaimer.html
To view the full press release, visit http://dtn.fm/MyB72
About IGC
IGC is engaged in the development of cannabis based combination therapies to treat Alzheimer’s, pain, nausea, eating disorders, several end points of Parkinson’s, and epilepsy in dogs and cats. IGC has assembled a portfolio of patent filings and four lead product candidates addressing these conditions. The company is based in Maryland, USA. For more information visit www.igcinc.us
About MissionIRNewsBreaks
MissionIRNewsBreaks provide a rapid summary of corporate news that catch the attention of MissionIR. MissionIRNewsBreaks are created by our Team of professional journalists that keep a constant eye on the markets, these posts are designed to inform you on the latest happenings of our clients and other publicly traded companies on our radar. From earnings, acquisitions and agreements to conference attendance and clinical study results, our news breaks keep you up-to-date with the day’s top movers. MissionIR is primarily focused on strategic communications. We have executed countless communications programs to address the needs of companies ranging from start-ups to established industry leaders, gaining valuable experience and the expertise necessary to determine the most effective strategy for any given situation.
MissionIR (MIR)
Atlanta, Georgia
www.MissionIR.com
404.941.8975 Office
Editor@MissionIR.com
Please see full terms of use and disclaimers on the Mission Investor Relations website applicable to all content provided by MIR, wherever published or re-published: http://www.missionir.com/disclaimer.html
Tuesday, October 3, 2017
AzurRx BioPharma, Inc. (NASDAQ: AZRX) Announces Encouraging Results in Phase IIa Trial for MS1819-SD
- Encouraging results noted for pancreatitis patients with exocrine pancreatic insufficiency
- Early data shows favorable safety profile, positive dose tolerance
- Favorable trends observed in other identified markers
- Study is being performed at four sites in Australia and New Zealand
New York-based AzurRx BioPharma Inc. (NASDAQ: AZRX), a biopharmaceutical company engaged in the research and development of non-systemic biologics for the treatment of patients with gastrointestinal disorders, recently announced positive results from its ongoing clinical trials of MS1819-SD, a recombinant lipase, developed for the treatment of exocrine pancreatic insufficiency (EPI) caused by chronic pancreatitis.
In an update issued last week (http://dtn.fm/njK0J), AzurRx BioPharma said clinical trials of the first six patients being treated with MS1819-SD underway in Australia and New Zealand are showing encouraging results. Importantly, the company said patients showed a positive dose response curve and a 21% improvement in the coefficient of fat absorption in evaluable patients. The response rate went as high as 57% in one of the patients, and higher response rates were noted in patients with lower baseline CFA levels. Favorable trends were also observed in other endpoints with no serious adverse events reported.
“We are encouraged by these Phase IIa data,” Thijs Spoor, CEO of AzurRx BioPharma, stated in the news release. “They further confirm the activity of MS1819-SD and also demonstrate its dose response characteristics. Additionally, secondary efficacy endpoints are consistently aligning with the CFA data and the safety profile of MS1819-SD remains favorable.”
The primary objective of the phase IIa study is to investigate the safety of escalating doses of MS1819-SD in patients with chronic pancreatitis. The secondary objective is to investigate the efficacy of MS1819-SD in these patients by analysis of the coefficient of fat absorption and its change from baseline. Patient safety is of paramount importance and is assessed at the end of each treatment period, with attention being paid to immunoallergic effects, digestive symptoms and clinical laboratory results.
AzurRx Biopharma expects to enroll 12-15 patients in this open-label phase IIa trial of MS1819-SD, which is being conducted in partnership with Mayoly Spindler, a European pharmaceutical company. There are approximately 100,000 patients in the U.S. with EPI caused by chronic pancreatitis, according to the National Pancreas Foundation, with another estimated 30,000 patients with EPI caused by cystic fibrosis, the Cystic Fibrosis Foundation reports. When the pancreas can’t properly break down foods, poor digestion and malnutrition is the result. Patients with this condition are currently treated with porcine (derived from pig) pancreatic enzyme replacement pills.
The National Institutes of Health, analysts on Wall Street and the National Pancreas Foundation estimate the yearly market for pancreatic enzyme replacement therapy to be well over $800 million in the U.S. and at least $1.5 billion globally.
For more information, visit the company’s website at www.AzurRx.com
About MissionIR
MissionIR is primarily focused on strategic communications. We have executed countless communications programs to address the needs of companies ranging from start-ups to established industry leaders, gaining valuable experience and the expertise necessary to determine the most effective strategy for any given situation.
For more information, visit www.MissionIR.com
MissionIR (MIR)
Atlanta, Georgia
www.MissionIR.com
404.941.8975 Office
Editor@MissionIR.com
Please see full terms of use and disclaimers on the Mission Investor Relations website applicable to all content provided by MIR, wherever published or re-published: http://www.missionir.com/disclaimer.html
MissionIRNewsBreaks – Moxian (NASDAQ: MOXC) Cashes in on China’s Growing Cashless Trend
Within the global market, consumer trends are ever tending toward the utilization of mobile devices when making purchases and otherwise connecting with businesses—something seen particularly among Chinese consumers. Well aware of China’s cashless trend, Moxian, Inc. (NASDAQ: MOXC) is cashing in by serving the online-to-offline (O2O) market with its Moxian User App and Business App—both of which feature UnionPay’s payment gateway. An article further discussing this reads: “China has 1.3 billion residents. A large number of them use smartphones, and three-quarters of all online payments are sent through mobile accounts, according to analyst estimates. Spending through mobile payment platforms in 2016 was 50-times as much as in the U.S. Consumers are increasingly opting to use resources such as the Moxian O2O marketplace rather than cash. MOXC’s social marketing and promotion platforms enable merchants to target mobile users in their advertising and better interact with consumers. Given the increasing popularity of mobile payments, the company’s solutions are expected to help merchants to continue to grow.”
To view the full article, visit http://dtn.fm/j2Ycq
About Moxian, Inc.
Founded in 2013 in Shenzhen, China with branch offices in Beijing, Malaysia, and Hong Kong, Moxian, Inc. is an offline-to-online (O2O) integrated platform operator. The Company’s “Moxian+” mobile App platform connects Users to Merchant Clients through games, rewards and social events that they enjoy and in return, Users provide valuable information that Merchant Clients can use to effectively promote products and services offered at their brick and mortar stores. More information about the Company can be found at www.moxian.com.
About MissionIRNewsBreaks
MissionIRNewsBreaks provide a rapid summary of corporate news that catch the attention of MissionIR. MissionIRNewsBreaks are created by our Team of professional journalists that keep a constant eye on the markets, these posts are designed to inform you on the latest happenings of our clients and other publicly traded companies on our radar. From earnings, acquisitions and agreements to conference attendance and clinical study results, our news breaks keep you up-to-date with the day’s top movers. MissionIR is primarily focused on strategic communications. We have executed countless communications programs to address the needs of companies ranging from start-ups to established industry leaders, gaining valuable experience and the expertise necessary to determine the most effective strategy for any given situation.
MissionIR (MIR)
Atlanta, Georgia
www.MissionIR.com
404.941.8975 Office
Editor@MissionIR.com
Please see full terms of use and disclaimers on the Mission Investor Relations website applicable to all content provided by MIR, wherever published or re-published: http://www.missionir.com/disclaimer.html
To view the full article, visit http://dtn.fm/j2Ycq
About Moxian, Inc.
Founded in 2013 in Shenzhen, China with branch offices in Beijing, Malaysia, and Hong Kong, Moxian, Inc. is an offline-to-online (O2O) integrated platform operator. The Company’s “Moxian+” mobile App platform connects Users to Merchant Clients through games, rewards and social events that they enjoy and in return, Users provide valuable information that Merchant Clients can use to effectively promote products and services offered at their brick and mortar stores. More information about the Company can be found at www.moxian.com.
About MissionIRNewsBreaks
MissionIRNewsBreaks provide a rapid summary of corporate news that catch the attention of MissionIR. MissionIRNewsBreaks are created by our Team of professional journalists that keep a constant eye on the markets, these posts are designed to inform you on the latest happenings of our clients and other publicly traded companies on our radar. From earnings, acquisitions and agreements to conference attendance and clinical study results, our news breaks keep you up-to-date with the day’s top movers. MissionIR is primarily focused on strategic communications. We have executed countless communications programs to address the needs of companies ranging from start-ups to established industry leaders, gaining valuable experience and the expertise necessary to determine the most effective strategy for any given situation.
MissionIR (MIR)
Atlanta, Georgia
www.MissionIR.com
404.941.8975 Office
Editor@MissionIR.com
Please see full terms of use and disclaimers on the Mission Investor Relations website applicable to all content provided by MIR, wherever published or re-published: http://www.missionir.com/disclaimer.html
MissionIRNewsBreaks – India Globalization Capital (NYSE: IGC) Demonstrates Potential in Alzheimer’s Treatment Market
In response to compelling recent data, India Globalization Capital, Inc. (NYSE MKT: IGC) announced it has made a highly significant novel breakthrough in treating Alzheimer’s disease with tetrahydrocannabinol (THC)—an advancement that could potentially bring much-needed relief to Alzheimer’s sufferers. A recent IGC press release (http://dtn.fm/c94Va) gave an update on in vitro data that has been compiled from genetically engineered cell lines in an Alzheimer’s disease model, demonstrating that, at varying THC concentrations, the aggregation of Aβ protein (the buildup of which has been linked to causing Alzheimer’s) decreases by up to 40 percent. An article further discussing this reads: “IGC stands to benefit in two ways: first, by taking IGC-ADI down the regular FDA route as both a prophylactic and a therapeutic; and second, as a food supplement to be sold in medical dispensaries. The FDA approach to a product labeled as a ‘drug’ is different to one classified as a ‘supplement.’ A drug is considered unsafe until proven otherwise by clinical trials, while a supplement, defined by the Dietary Supplement Health and Education Act (DSHEA) as food, is considered to be prima facie safe. This binal approach allows IGC to secure market share in the medical dispensary segment while IGC-AD1, named Hyalolex, works its way through the FDA approval process.”
To view the full article, visit http://dtn.fm/mm4Vh
About IGC
IGC is engaged in the development of cannabis based combination therapies to treat Alzheimer’s, pain, nausea, eating disorders, several end points of Parkinson’s, and epilepsy in dogs and cats. IGC has assembled a portfolio of patent filings and four lead product candidates addressing these conditions. The company is based in Maryland, USA. For more information please visit www.igcinc.us.
About MissionIRNewsBreaks
MissionIRNewsBreaks provide a rapid summary of corporate news that catch the attention of MissionIR. MissionIRNewsBreaks are created by our Team of professional journalists that keep a constant eye on the markets, these posts are designed to inform you on the latest happenings of our clients and other publicly traded companies on our radar. From earnings, acquisitions and agreements to conference attendance and clinical study results, our news breaks keep you up-to-date with the day’s top movers. MissionIR is primarily focused on strategic communications. We have executed countless communications programs to address the needs of companies ranging from start-ups to established industry leaders, gaining valuable experience and the expertise necessary to determine the most effective strategy for any given situation.
MissionIR (MIR)
Atlanta, Georgia
www.MissionIR.com
404.941.8975 Office
Editor@MissionIR.com
Please see full terms of use and disclaimers on the Mission Investor Relations website applicable to all content provided by MIR, wherever published or re-published: http://www.missionir.com/disclaimer.html
To view the full article, visit http://dtn.fm/mm4Vh
About IGC
IGC is engaged in the development of cannabis based combination therapies to treat Alzheimer’s, pain, nausea, eating disorders, several end points of Parkinson’s, and epilepsy in dogs and cats. IGC has assembled a portfolio of patent filings and four lead product candidates addressing these conditions. The company is based in Maryland, USA. For more information please visit www.igcinc.us.
About MissionIRNewsBreaks
MissionIRNewsBreaks provide a rapid summary of corporate news that catch the attention of MissionIR. MissionIRNewsBreaks are created by our Team of professional journalists that keep a constant eye on the markets, these posts are designed to inform you on the latest happenings of our clients and other publicly traded companies on our radar. From earnings, acquisitions and agreements to conference attendance and clinical study results, our news breaks keep you up-to-date with the day’s top movers. MissionIR is primarily focused on strategic communications. We have executed countless communications programs to address the needs of companies ranging from start-ups to established industry leaders, gaining valuable experience and the expertise necessary to determine the most effective strategy for any given situation.
MissionIR (MIR)
Atlanta, Georgia
www.MissionIR.com
404.941.8975 Office
Editor@MissionIR.com
Please see full terms of use and disclaimers on the Mission Investor Relations website applicable to all content provided by MIR, wherever published or re-published: http://www.missionir.com/disclaimer.html
Monday, October 2, 2017
Moxian, Inc. (NASDAQ: MOXC) Platforms Connect Businesses and Consumers as the Mobile Payments Market Expands
- Nearly half of consumers in China pay using mobile devices
- Three-quarters of online payments come through mobile accounts
- Moxian’s apps serve consumers and businesses in the O2O market
The current trends in the global market are encouraging to investors, as consumers increasingly use mobile devices to connect with businesses and make purchases. Moxian, Inc. (NASDAQ: MOXC) recently cited data published by Nielson, in its Global Mobile Money Report (http://dtn.fm/KaG5y), indicating that, in China, nearly half of consumers are likely to use a device when paying a bill at a restaurant, store or bar. The ratio is even higher than in the U.S. and Europe. Mobile payments are growing on a global scale. A forecast by Allied Market Research, in its Mobile Payments Market Report, predicts that the global market may surpass $3.3 billion by 2022, expanding at a compound annual growth rate of 33.4 percent from 2016 to 2022 (http://dtn.fm/5o3Su).
The highest growth, according to the report, is expected to be in the Asia-Pacific region. Moxian has been well aware of the cashless trend in China. It serves the online-to-offline (O2O) market with its Moxian User App and Business App. Both of these feature UnionPay’s payment gateway. This integral system works with Moxian’s MO-Coin and MO-Points virtual currency, so consumers can take advantage of rewards features in the latest app versions.
The User App enables customers to earn MO-Coins by playing games, which they can redeem for prizes. This functionality enables merchants to run their marketing campaigns and advertise to their customers. It helps to learn a great deal about consumer behavior, while users can search for local merchants and obtain news and communicate with friends using the app’s media messenger. Moxian’s Multi-Channel Social Commerce Platform further digs into customer data using business intelligence, social media and entertainment.
Featuring a Social Customer Relationship Management Tool, the Moxian Business App is helping serve the regional market by providing merchants with the ability to establish virtual stores on the company’s platform. It supports various methods of promotion. In addition, customized reports are generated to provide business with insights into purchasing and other customer activity.
Businesses can also leverage automated data analytics tools. The app captures data automatically, so retailers can get the most out of the tools available. These include a loyalty tool that helps enhance marketing strategies. Companies can advertise directly through the platform, as well using a variety of media.
China has 1.3 billion residents. A large number of them use smartphones, and three-quarters of all online payments are sent through mobile accounts, according to analyst estimates. Spending through mobile payment platforms in 2016 was 50-times as much as in the U.S. Consumers are increasingly opting to use resources such as the Moxian O2O marketplace rather than cash. MOXC’s social marketing and promotion platforms enable merchants to target mobile users in their advertising and better interact with consumers. Given the increasing popularity of mobile payments, the company’s solutions are expected to help merchants to continue to grow.
For more information, visit the company’s website at www.Moxian.com
About MissionIR
MissionIR is primarily focused on strategic communications. We have executed countless communications programs to address the needs of companies ranging from start-ups to established industry leaders, gaining valuable experience and the expertise necessary to determine the most effective strategy for any given situation.
For more information, visit www.MissionIR.com
MissionIR (MIR)
Atlanta, Georgia
www.MissionIR.com
404.941.8975 Office
Editor@MissionIR.com
Please see full terms of use and disclaimers on the Mission Investor Relations website applicable to all content provided by MIR, wherever published or re-published: http://www.missionir.com/disclaimer.html
Subscribe to:
Posts (Atom)